OKYO Pharma Limited (EMMLF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to OKYO Pharma Limited (EMMLF) stock?
OKYO Pharma Limited (EMMLF) no longer trades on public markets. The figures below are historical and are not a current quote.
Market cap $22.7M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
OKYO Pharma Limited (EMMLF). OKYO Pharma Limited is a preclinical biopharmaceutical company focused on developing therapies for inflammatory eye diseases and ocular pain. Market cap: $22.7M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for EMMLF: EMMLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EMMLF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
EMMLF: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
OKYO Pharma Limited (EMMLF) Healthcare & Pipeline Overview
OKYO Pharma Limited is a preclinical biopharmaceutical company specializing in developing novel therapeutics for inflammatory eye diseases and ocular pain, primarily focusing on dry eye disease with its lead product OK-101, operating within the competitive biotechnology sector in the United Kingdom.
What Is the Investment Thesis for EMMLF?
OKYO Pharma Limited presents a speculative investment opportunity due to its early-stage pipeline focused on addressing significant unmet needs in ophthalmology. The company's lead product, OK-101, targets the dry eye disease market, estimated at billions of dollars globally. Successful clinical trials and subsequent regulatory approval could drive substantial revenue growth. The development of OK-201 for neuropathic ocular pain offers further potential upside. However, the company faces significant risks associated with preclinical drug development, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $22.7M and a negative P/E ratio of -13.06, the company's valuation is highly dependent on the successful advancement of its pipeline.
Based on FMP financials and quantitative analysis
EMMLF Key Highlights
OKYO Pharma Limited is a preclinical biopharmaceutical company focused on inflammatory eye diseases and ocular pain.
- Lead product OK-101 is in development for the treatment of dry eye disease.
- Developing OK-201 for neuropathic ocular pain.
- The company is headquartered in London, United Kingdom.
- Market capitalization of $22.7M indicates a small-cap company.
Who Are EMMLF's Competitors?
EMMLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | 0.00% | $16.5M | — |
| IBXNF IBEX Technologies Inc. | $1.00 | -6.54% | $25.3M | — |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | — |
| OCEL Organicell Regenerative Medicine, Inc. | $2.74 | -0.27% | $20.0M | — |
| OPBXF OptiBiotix Health Plc | $0.22 | 0.00% | $20.1M | — |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EMMLF's Key Strengths?
Novel lipidated-peptide technology platform.
- Focus on unmet needs in ophthalmology.
- Lead product targeting a large market (dry eye disease).
- Experienced management team.
What Are EMMLF's Weaknesses?
Preclinical stage of development.
- Limited financial resources.
- Dependence on successful clinical trials.
- Small number of employees.
What Could Drive EMMLF Stock Higher?
Initiation of clinical trials for OK-101 for dry eye disease.
- Preclinical data release for OK-201 for neuropathic ocular pain.
- Pursuit of strategic partnerships with pharmaceutical companies.
- Expansion of intellectual property portfolio.
What Are the Key Risks for EMMLF?
Clinical trial failures for OK-101 or OK-201.
- Regulatory delays or rejection of drug approvals.
- Competition from established pharmaceutical companies.
- Limited financial resources to fund research and development.
- Inability to secure strategic partnerships.
What Are the Growth Opportunities for EMMLF?
- Expansion of OK-101 into new geographic markets: Following successful clinical trials and regulatory approval in the United Kingdom or the United States, OKYO Pharma could expand its commercial reach into other regions with a high prevalence of dry eye disease, such as Europe and Asia. This geographic expansion could significantly increase revenue potential, tapping into a global market estimated at billions of dollars.
- Development of new formulations or delivery methods for OK-101: OKYO Pharma could explore developing new formulations of OK-101, such as sustained-release or preservative-free options, to improve patient compliance and efficacy. Additionally, exploring alternative delivery methods, such as topical gels or eye drops, could enhance the product's appeal and market penetration. This would require further R&D investment but could yield a more competitive product.
- Advancement of OK-201 into clinical trials: Successful preclinical development of OK-201 for neuropathic ocular pain could lead to the initiation of clinical trials, representing a significant milestone for the company. Positive clinical trial results would validate the potential of OK-201 as a novel treatment option and attract potential partnerships or acquisition interest. The neuropathic ocular pain market represents a significant unmet need, offering substantial commercial opportunities.
- Strategic partnerships with pharmaceutical companies: OKYO Pharma could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline products. These partnerships could provide access to funding, expertise, and established distribution networks, increasing the likelihood of successful product launches and market penetration. This would allow OKYO to focus on its core competencies in research and development.
- Expansion into new therapeutic areas within ophthalmology: Leveraging its expertise in lipidated-peptide technology, OKYO Pharma could expand its pipeline to include therapies for other ophthalmic conditions, such as glaucoma or age-related macular degeneration. This diversification would reduce the company's reliance on its current pipeline and create new growth opportunities in a rapidly expanding market. This would require significant investment in research and development.
What Are EMMLF's Competitive Advantages?
- Proprietary lipidated-peptide technology platform.
- Patents protecting its therapeutic compounds.
- First-mover advantage in targeting specific inflammatory eye diseases.
What Does EMMLF Do?
OKYO Pharma Limited, established in 2007 and headquartered in London, is a preclinical biopharmaceutical company dedicated to the discovery and development of innovative therapies for inflammatory eye diseases and ocular pain. The company's primary focus is on addressing unmet needs in the treatment of dry eye disease and neuropathic ocular pain. Their lead product, OK-101, is being developed as a novel treatment for dry eye disease, a condition affecting millions worldwide. Additionally, OKYO Pharma is advancing OK-201, a preclinical analogue candidate, targeting neuropathic ocular pain. The company operates primarily in the United Kingdom, conducting research and development activities to advance its pipeline of therapeutic candidates. OKYO Pharma's strategy involves leveraging its expertise in lipidated-peptide technology to create targeted therapies with improved efficacy and safety profiles. The company aims to partner with larger pharmaceutical companies to commercialize its products upon successful completion of clinical trials.
What Products and Services Does EMMLF Offer?
- Develop therapeutics for inflammatory eye diseases.
- Focus on treatments for ocular pain.
- Develop OK-101 for dry eye disease.
- Develop OK-201 for neuropathic ocular pain.
- Conduct preclinical research and development.
- Utilize lipidated-peptide technology.
How Does EMMLF Make Money?
- Develops and patents novel therapeutic compounds.
- Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
- Focuses on preclinical research and early-stage development.
What Industry Does EMMLF Operate In?
OKYO Pharma Limited operates within the biotechnology industry, specifically targeting the ophthalmology market. This market is characterized by increasing prevalence of eye diseases such as dry eye disease and neuropathic ocular pain, driven by factors like aging populations and increased screen time. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel therapies. OKYO Pharma aims to differentiate itself through its lipidated-peptide technology and targeted approach to drug development.
Who Are EMMLF's Key Customers?
- Future patients suffering from dry eye disease.
- Future patients suffering from neuropathic ocular pain.
- Potential pharmaceutical partners for licensing agreements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 44 |
| 2026-08-24 | 44 |
| 2026-08-25 | 44 |
| 2026-08-26 | 44 |
What changed?
The score has stayed at 44.
Over the same 3 days the stock moved +0.0%.
How OKYO Pharma Limited Is Valued
OKYO Pharma Limited carries a market capitalization of $22.7M, placing it in the micro-cap category.
Company Profile
OKYO Pharma Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Gary S. Jacob. EMMLF has traded publicly since 2020.
Key Financial Metrics
Return on assets is -42.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.43 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.3%, the inverse of the P/E and a quick read on earnings relative to price.
EMMLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel lipidated-peptide technology platform.
- Focus on unmet needs in ophthalmology.
- Lead product targeting a large market (dry eye disease).
- Experienced management team.
Bear Case
- Preclinical stage of development.
- Limited financial resources.
- Dependence on successful clinical trials.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EMMLF Latest News
No recent news available for EMMLF.
Leadership: Gary S. Jacob
CEO
Gary S. Jacob serves as the CEO of OKYO Pharma Limited. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, overseeing research and development programs, clinical trials, and regulatory affairs. His expertise spans multiple therapeutic areas, including ophthalmology. He is responsible for guiding OKYO Pharma's strategic direction and advancing its pipeline of therapeutic candidates.
Track Record: Under Gary S. Jacob's leadership, OKYO Pharma has focused on advancing its lead product, OK-101, through preclinical development and preparing for clinical trials. He has overseen the expansion of the company's intellectual property portfolio and the establishment of strategic partnerships. His leadership is focused on securing funding and advancing the company's pipeline.
EMMLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that OKYO Pharma Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can increase the risk for investors, as less information is available to assess the company's financial health and operations compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Consider the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has a website and contact information.
- Company has a clear business plan and product pipeline.
- Company has patents or intellectual property.
- Company is actively seeking funding and partnerships.
- CEO has relevant experience in the pharmaceutical industry.
OKYO Pharma Limited Healthcare Stock: Key Questions Answered
What happened to OKYO Pharma Limited (EMMLF) stock?
OKYO Pharma Limited (EMMLF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy EMMLF shares?
No. EMMLF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for EMMLF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EMMLF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to OKYO Pharma Limited. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does OKYO Pharma Limited do?
OKYO Pharma Limited is a preclinical biopharmaceutical company focused on developing novel therapeutics for inflammatory eye diseases and ocular pain. Their primary focus is on addressing unmet needs in the treatment of dry eye disease with their lead product, OK-101, and neuropathic ocular pain with OK-201.
What do analysts say about EMMLF stock?
As of 2026-03-17, there is no available analyst coverage for EMMLF. Given its status as an OTC-listed, preclinical-stage biopharmaceutical company, analyst coverage is likely limited.
What are the main risks for EMMLF?
The main risks for OKYO Pharma Limited include the inherent uncertainties associated with preclinical drug development, such as clinical trial failures and regulatory hurdles.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.